Table 3 Composition of ADCs targeting gastric cancer.
NCI thesaurus code | ADC | Therapeutic target | Antibody | Payload | Linker | DAR |
|---|---|---|---|---|---|---|
C169918 | RC48 | HER2 | Hertuzumab | MMAE | VC | 4 |
C82429 | T-DM1 | HER2 | Trastuzumab | DM1 | SMCC | 3.5 |
C128799 | DS-8201a | HER2 | Trastuzumab | DXd | Tetrapeptide | 8 |
C123917 | ARX788 | HER2 | Anvatabart | Amberstatin269 | pAcF | 1.9 |
C174205 | MRG002 | HER2 | Trastuzumab | MMAE | VC | 3.8 |
C172821 | LCB-ADC | HER2 | Trastuzumab | MMAF | Undisclosed | 2 |
C132112 | XMT-1522 | HER2 | HT-19 | AF-HPA | Fleximer polymer | 12 |
C118674 | SYD985 | HER2 | Trastuzumab | Duocarmycin | VC | 2.8 |
C173966 | BAT8001 | HER2 | Trastuzumab | Maytansine | 6-Maleimidocaproic acid | / |
C162115 | ZW49 | HER2 | ZW25 | N-acyl | Protease | 2 |
C101524 | TAK-264 | GCC | Indusatumab | MMAE | VC | 7.4 |
C156707 | TAK-164 | GCC | 5F9 | DGN549 | Peptidic | / |
[150] | EV20/NMS-P945 | HER3 | EV20 | NMS-P945 | Peptidic | 3.6 |
C136987 | U3-1402 | HER3 | Patritumab | DXd | Tetrapeptide | 8 |
C180413 | CMG901 | CLDN18.2 | mAb | MMAE | Undisclosed | 8 |
C190788 | SOT102 | CLDN18.2 | IgG1 mAb | PNU-159682 | Amide/peptide | 2 |
C102783 | IMMU-132 | TROP2 | hRS7 | SN-38 | CL2A | 7.6 |
C166409 | SKB264 | TROP2 | Sacituzumab | T030 | CL2A | 7.4 |
[173] | Nectin-4 NDC | Nectin-4 | Nb | MMAE | maleimide | 1 |
